STOFF 2016

December 8 - 11, 2016 Cary, North Carolina Program Brochure (PDF)

Key Meeting Topics

Phase I Clinical Trials: Hypothesis Testing Pharmacogenomics Immune Checkpoint Inhibition in Advanced Cancer Oncology Drug Development: A Regulatory Perspective

Presentation Summaries

Oncology Drug Development: Honest Views from an Academic
Bernardo Goulart, MD, MS
Summary (PDF)


Precision Medicine: Myth or Reality
Bruce A. Chabner, MD
Summary (PDF)


Phase 1 Clinical Trials: Hypothesis Testing
Keith T. Flaherty, MD
Summary (PDF)


New Drug Development in 2016: Progress, Challenges, and Prices
Thomas G. Roberts, Jr., MD, MSoc Sci
Summary (PDF)


National Cancer Moonshot – Blue Ribbon Panel ®
Deborah Mayer, PhD, RN, AOCN, FAAN
Summary (PDF)


Data Sharing, Research Parasites, and the Korean Alphabet
Geoffrey Kim, MD
Summary (PDF)


The Cancer Genome Atlas (TCGA)
William Kim, MD
Summary (PDF)


Guidelines for Good Scientific Practice
Mark W. Duncan, PhD
Summary (PDF)


Immune Checkpoint Inhibition in Advanced Cancer
Michael Postow, MD
Summary (PDF)


Pharmacogenomics
Peter H. O’Donnell, MD
Summary (PDF)


Receptor-Associated Kinase Inhibitor / Intracellular Resistance Pathways
Jeffrey Engelman, MD, PhD
Summary (PDF)


How to Write a Grant
Keith T. Flaherty, MD
Summary (PDF)


Oncology Drug Development: A Regulatory Perspective
Tatiana Prowell, MD
Summary (PDF)
Acknowledgments

Summaries were created from the proceedings of the Society for Translational Oncology Fellows’ Forum held on December 8-11, 2016 in Cary, NC.

The Society for Translational Oncology gratefully acknowledges support of this activity from:

 


Privacy Policy | Terms of Use | Contact Us

Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.